Reneo股东批准与OnKure合并

2024-10-03 18:05

Reneo Pharmaceuticals (NASDAQ:RPHM) stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure.
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines.
The closing of the merger is anticipated to take place on or around Friday, October 4, 2024.
The combined company plans to change its name from “Reneo Pharmaceuticals, Inc.” to “OnKure Therapeutics, Inc.” and trade on Nasdaq under the ticker symbol “OKUR.”
In addition, Reneo (RPHM) also announced that it will effect a 1-for-10 reverse split that is expected to be effective immediately prior to the closing of the merger.

More on Reneo Pharmaceuticals